Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection

Journal of Clinical Pharmacology

Volumn 54, Issue 9, 2014, Pages 1058-1062

  Eslam, Roza Badr ^a   Burian, Angela ^a   Vila, Greisa ^a   Sauermann, Robert ^a   Hammer, Alexandra ^a   Frenzel, Dorothea ^b   Minichmayr, Iris K ^c   Kloft, Charlotte ^b,c   Matzneller, Peter ^a   Oesterreicher, Zoe ^a   Zeitlinger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

inflammation; linezolid; pharmacokinetics; tissue

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC PATIENT; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; SOFT TISSUE INFECTION; STEADY STATE; SUBCUTANEOUS FAT; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; FOOT DISEASES; METABOLISM; MIDDLE AGED; SOFT TISSUE INFECTIONS; VERY ELDERLY;

ACETAMIDES; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DIABETES MELLITUS, TYPE 2; FEMALE; FOOT DISEASES; HUMANS; MALE; MICRODIALYSIS; MIDDLE AGED; OXAZOLIDINONES; SOFT TISSUE INFECTIONS;

EID: 84905577216     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.296     Document Type: Article

References (20)

1. Wild S, Roglic G, Green A, Sicree R, King H,. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27 (5): 1047-1053.
2. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006; 45 (5 Suppl): S1-S66.
3. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C,. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49 (6): 2260-2266.
4. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP,. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother. 2011; 55 (9): 4170-4175.
5. Eckmann C, Dryden M,. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010; 15 (12): 554-563.
6. Muller M, Schmid R, Georgopoulos A, Buxbaum A, Wasicek C, Eichler HG,. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther. 1995; 57 (4): 371-380.
7. Sauermann R, Burian B, Burian A, et al. Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections. J Antimicrob Chemother. 2013; 68 (4): 895-899.
8. Dehghanyar P, Burger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005; 49 (6): 2367-2371.
9. Buerger C, Joukhadar C, Muller M, Kloft C,. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B. 2003; 796 (1): 155-164.
10. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN,. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother. 2013; 57 (2): 1077-1081.
11. Draghi DC, Sheehan DJ, Hogan P, Sahm DF,. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother. 2005; 49 (12): 5024-5032.
12. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR,. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother. 2012; 56 (11): 5916-5922.
13. Inc T,. Biopharmaceutics Classification System (BCS). http://1667814201/tsrlinccom/services/bcs/resultscfm. February 20, 2014.
14. Lemaire S, Van Bambeke F, Pierard D, Appelbaum PC, Tulkens PM,. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis. 2011; 52 (Suppl 7): S493-S503.
15. Stalker DJ, Jungbluth GL,. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial20. Clin Pharmacokinet. 2003; 42 (13): 1129-1140.
16. Rebuelto M,. Chronopharmacology and antimicrobial therapeutics. Curr Clin Pharmacol. 2006; 1 (3): 265-275.
17. Traunmuller F, Schintler MV, Spendel S, et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents. 2010; 36 (1): 84-86.
18. Ambrosch A, Haefner S, Jude E, Lobmann R,. Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus. Int Wound J. 2011; 8 (6): 567-577.
19. Ager S, Gould K,. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist. 2012; 5: 87-102.
20. Rawat V, Singhai M, Kumar A, Jha PK, Goyal R,. Bacteriological and resistance profile in isolates from diabetic patients. N Am J Med Sci. 2012; 4 (11): 563-568.